Drug intelligence / Profile preview

HLK-0003

Development stage: Unknown
Lead developer: HLK Pharmacin
Modality: Small Molecules
Administration: Oral

Overview

HLK-0003 is an investigational drug candidate developed by Shenzhen Pharmacin (also known as Pharmacin (Shenzhen) Co., Ltd.) for the treatment of neurologic disorders. The drug is developed using the company's proprietary SpraySol™ technology, a solid dispersion platform designed to enhance the solubility and bioavailability of poorly water-soluble compounds. HLK-0003 is being developed via the FDA's 505(b)(2) regulatory pathway, which typically involves new formulations, strengths, or delivery methods of previously approved active pharmaceutical ingredients. It is currently in early clinical development, progressing through the Phase 1 or Investigator-Initiated Trial (IIT) stage.

Beyond the preview

Go deeper on HLK-0003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-0003.

Explore the full profile